Analysts Issue Forecasts for SGMO Q4 Earnings

Key Points

• HC Wainwright projects Sangamo Therapeutics' Q4 2026 earnings per share (EPS) at $0.01, while the full-year estimate is currently at ($0.46) per share.
• The company's most recent earnings were disappointing, reporting ($0.08) EPS and missing estimates, with revenues of $18.31 million falling short of the expected $31.68 million.
• Analyst ratings are mixed, with one sell rating, two hold ratings, and four buy ratings, while the average price target has been set around $4.50.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Equities researchers at HC Wainwright issued their Q4 2026 earnings per share (EPS) estimates for Sangamo Therapeutics in a research note issued to investors on Tuesday, August 12th. HC Wainwright analyst P. Trucchio forecasts that the biopharmaceutical company will earn $0.01 per share for the quarter. HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics' FY2029 earnings at $0.33 EPS.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $18.31 million during the quarter, compared to analysts' expectations of $31.68 million. Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%.

Several other brokerages have also issued reports on SGMO. Barclays dropped their price objective on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Wall Street Zen cut Sangamo Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, May 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Sangamo Therapeutics currently has an average rating of "Hold" and an average price target of $4.50.

Sangamo Therapeutics Stock Performance

Shares of SGMO stock traded down $0.00 during mid-day trading on Thursday, hitting $0.54. 2,052,078 shares of the stock were exchanged, compared to its average volume of 6,082,682. The stock's fifty day simple moving average is $0.52 and its two-hundred day simple moving average is $0.71. The stock has a market capitalization of $125.21 million, a price-to-earnings ratio of -1.84 and a beta of 1.18. Sangamo Therapeutics has a 12-month low of $0.41 and a 12-month high of $3.18.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SGMO. JPMorgan Chase & Co. raised its holdings in Sangamo Therapeutics by 679.5% in the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 21,793 shares during the last quarter. Captrust Financial Advisors acquired a new position in Sangamo Therapeutics in the 4th quarter valued at $30,000. LPL Financial LLC raised its holdings in Sangamo Therapeutics by 113.5% in the 4th quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 16,498 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Sangamo Therapeutics in the 4th quarter valued at $47,000. Finally, R Squared Ltd acquired a new position in Sangamo Therapeutics in the 2nd quarter valued at $28,000. 56.93% of the stock is currently owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.